Anavex Life Sciences Corp (AVXL)

[OFP]

These new results provide converging evidence on mechanism of action as well as possible disease-modifying properties potentially by restoring homeostasis by means of the sigma-1 receptor agonists in our pipeline. This data also provides a foundation for our ongoing translational research efforts

So again he is trying to co-opt generic S1R agonist effects as a 2-73 MOA. That is fine as long as you don't expect 2-73 to outperform other S1R agonists.

There is no measure assessed in that study in which 2-73 outperformed. OTOH 2-73 did underperform in multiple measures including some in which DZP was available as a comparator.